Skip Navigation


Journal of Pediatric Psychology Advance Access originally published online on April 18, 2007
Journal of Pediatric Psychology 2007 32(9):1111-1126; doi:10.1093/jpepsy/jsm012
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
32/9/1111    most recent
jsm012v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Daly, B. P.
Right arrow Articles by Brown, R. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Daly, B. P.
Right arrow Articles by Brown, R. T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press on behalf of the Society of Pediatric Psychology. All rights reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org

Scholarly Literature Review: Management of Neurocognitive Late Effects with Stimulant Medication

Brian P. Daly, PhD and Ronald T. Brown, PhD

Temple University, Philadelphia

All correspondence concerning this article should be addressed to Brian P. Daly, PhD, Department of Public Health, Temple University, 3307 North Broad Street, Philadelphia, PA 19140. E-mail: brian.daly{at}temple.edu. The review of this manuscript was managed by John V. Lavigne, PhD


  Abstract

Objective To examine the extant literature on stimulant drug therapy for survivors of childhood cancer during the late-effects period. Methods A review of literature is provided on the mechanism of and cognitive toxicities for children and adolescents treated for acute lymphoblastic leukemia (ALL) and malignant brain tumors (BT) as well as the pharmacotherapy of stimulant medications, with a specific review of literature on the efficacy and safety of the stimulants for children with ALL and BT. Results Only four studies were found that have examined the effects of stimulant medication on the cognitive toxicities of childhood survivors of cancer during the late-effects period and only two of these investigations were controlled clinical trials. Findings suggest efficacy of the stimulants on parent and teacher ratings of attention and putative tasks of attention and executive functioning. Conclusions Although there is some preliminary support for the efficacy and safety of the stimulants for survivors of ALL and BT, more research is needed concerning the long-term effects of the stimulants among cancer survivors.

Key words: neurocognitive late effects; childhood cancer; stimulants; acute lymphoblastic leukemia; malignant brain tumors..

Received October 4, 2006; revision received January 15, 2007; accepted February 3, 2007


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Pediatr PsycholHome page
M. J. Bonner, K. K. Hardy, V. W. Willard, K. K. Anthony, M. Hood, and S. Gururangan
Social Functioning and Facial Expression Recognition in Survivors of Pediatric Brain Tumors
J. Pediatr. Psychol., April 5, 2008; (2008) jsn035v1.
[Abstract] [Full Text] [PDF]

Home page
 J Pediatr PsycholHome page
L. Kun and R. T. Brown
Introduction to the Special Issue: A Tribute to the Life of Raymond K. Mulhern
J. Pediatr. Psychol., October 1, 2007; 32(9): 1025 - 1028.
[Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.